HEART AND BONE HEALTH
Vitamin K2 MK7
K2VITAL – Your Key to Optimal Bone Health
Vitamin K2 acts as a co-factor necessary for activation of osteocalcin, which facilitates binding of calcium to bones. When activated, osteocalcin enables calcium to be incorporated into the bone matrix (hydroxyapatite) and thereby build new bone.
The active compound in K2VITAL is vitamin K2 in its natural form, the most efficient form of vitamin K; MK-7. Vitamin K2 is tested in numerous clinical trials and K2VITAL is documented as safe.
Vitamin K2 and effects on bone health
Clinical studies focusing on parameters important for bone health are long-term studies involving computerized scanning analysis of bone mineral density (BMD), bone mineral content (BMC) and bone strength as well as scores for bone fractures (hip, arm, vertebra). Several studies have demonstrated favorable bone health effect of vitamin K2, especially with respect to bone strength and reduced incidences of bone fractures. Most studies have been carried out with high doeses (drug doses) of vitamin K2 as MK-4. Studies on effects of vitamin K2 as MK-7 are mainly based on intake of Natto (the traditionally dish in Japan based on fermented soybeans) in Japan. Natto has a high content of MK-7 and people eating natto has lower incidence of fractures.
K2VITAL – Your Key to Optimal Blood Circulation
Vitamin K2 acts as a co-factor for activation of Matrix Gla Protein (MGP), located in the cartilage and smooth muscle cells of the vascular system. In its activated form, MGP is known as the strongest inhibitor of soft tissue calcification, including cartilage mineralization.
Cardiovascular Diseases – a major health issue
Cardiovascular disease (CVD) is one of the leading causes of death in the Western world. An estimated 17 million people die of CVDs every year, particularly heart attacks and strokes (WHO); representing 29% of all global deaths. More than 50% of patients diagnosed with chronic heart failure (CHF) die within 5 years of initial diagnosis. Morbidity and mortality from peripheral arterial disease (PAD) are even higher than from coronary artery disease (CAD). By 2030, almost 23.6 million people will die from CVD’s, mainly from heart disease and stroke. These are projected to remain the single leading causes of death.